Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			Pre-market 12:05:48
138.99 ^USD	-2.18%		137.84	-0.82%

04-10	Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $115 From $155, Maintains Overweight Rating	MT
04-09	Tempus AI, Inc. And Gilead Sciences, Inc. Announce Strategic Collaboration To Advance Oncology R&D	CI

Analyst Reco.

04-10	Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $115 From $155, Maintains Overweight Rating	MT
04-08	Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says	MT
04-07	RBC Adjusts Price Target on Gilead Sciences to $123 From $118, Maintains Sector Perform Rating	MT
03-31	Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says	MT
02-25	Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating	MT
02-25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
02-24	Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says	MT
02-20	Barclays Initiates Coverage on Gilead Sciences With Equal Weight Rating	MT
02-19	Argus Adjusts Price Target on Gilead Sciences to $165 From $135, Maintains Buy Rating	MT
02-18	Mizuho Securities Lifts Gilead Sciences Price Target to $170 From $140, Maintains Outperform Rating	MT
02-17	Rothschild & Co Redburn Adjusts Gilead Sciences PT to $170 From $159, Maintains Buy Rating	MT
02-16	Analyst recommendations: Eagle Materials, Coinbase Global, Gilead Sciences, Royal Gold…
02-12	Wolfe Adjusts Price Target on Gilead Sciences to $170 From $155, Maintains Outperform Rating	MT
02-11	TD Cowen Adjusts Gilead Sciences Price Target to $160 From $145, Maintains Buy Rating	MT
02-11	Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says	MT
02-11	Deutsche Bank Adjusts Gilead Sciences Price Target to $155 From $135, Maintains Buy Rating	MT
02-11	Oppenheimer Adjusts PT on Gilead Sciences to $165 From $128, Maintains Outperform Rating	MT
02-11	Leerink Partners Adjusts Gilead Sciences PT to $148 From $146, Maintains Outperform Rating	MT
02-11	RBC Raises Price Target on Gilead Sciences to $118 From $103, Keeps Sector Perform Rating	MT
02-11	Morgan Stanley Raises Price Target on Gilead Sciences to $171 From $150, Keeps Overweight Rating	MT
02-11	JPMorgan Adjusts Price Target on Gilead Sciences to $160 From $150, Maintains Overweight Rating	MT
02-11	Wells Fargo Adjusts Price Target on Gilead Sciences to $165 From $150, Maintains Overweight Rating	MT
02-11	Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $135, Maintains Overweight Rating	MT
02-11	Needham Adjusts Price Target on Gilead Sciences to $170 From $140, Maintains Buy Rating	MT
02-11	BMO Capital Adjusts Price Target on Gilead Sciences to $160 From $150, Maintains Outperform Rating	MT